Cancer Research Horizons opens nominations for its Innovation & Entrepreneurship Awards 2024

Cancer Research Horizons, the innovation arm of Cancer Research UK, has opened nominations for its Innovation & Entrepreneurship Awards 2024, which celebrate the UK’s most enterprising efforts in oncology by recognising the researchers and entrepreneurs who are making strides towards translating their innovations into effective treatments and diagnostics for the benefit of patients affected by cancer.

Nominations close at 5pm on 10 January 2024 and can be submitted for multiple categories via self-nomination or by someone else. Nominations do not need to be funded by Cancer Research UK but must be based in the UK. All nominations will be reviewed by a judging panel of independent experts, which will be announced in the future. Award winners will receive funding, sector-wide recognition, and the chance to inspire the next generation of academic entrepreneurs.

All shortlisted nominees will be invited to attend the awards ceremony at The Law Society on 20 March 2024, where the winners will be announced. For team nominations, up to three representatives will be invited. This black-tie event includes a drinks reception and gala dinner, providing a unique opportunity to network with a range of rising stars, seasoned entrepreneurs, industry experts, and inspiring keynotes.

The following five awards are open for nominations:

  • Early Career Entrepreneur of the Year (nominate here)
    Entrepreneurial Group Leader of the Year (nominate here)
  • Woman Entrepreneur of the Year (nominate here)
  • New Startup of the Year (nominate here)
  • Further, Faster, Together (Industry–Academia Collaboration) (nominate here)

There will also be three special awards to recognise outstanding contributions to the academic cancer entrepreneurial field, which are not open to nominations; instead, the judging panel will select winners from shortlists identified by Cancer Research Horizons.

 

More news and updates 

Aleta Biotherapeutics and Cancer Research UK announce first patient dosed in ALETA-001 Phase 1/2 clinical trial

The Phase 1/2 clinical trial will evaluate safety, dose, PK/PD, and early efficacy signals of Aleta’s first-in-class biologic CAR T-cell engager, ALETA-001. ALETA-001 entering the clinic is a critical milestone toward treatment availability to improve CAR T-cell patient response when a complete response is not achieved or maintained.

UKHSA announced as first PACE collaboration to help tackle deadly antimicrobial resistance

Strategic partnership to support AMR innovators

PrecisionLife and Metrodora Institute partner to accelerate diagnosis of Long COVID

Rapid development and clinical validation of diagnostics that enable innovative clinical care pathways in complex, chronic diseases; targeted precision medicine clinical trials leveraging a complementary diagnostic approach are expected to readout results as early as this year

Optibrium enables collaborative design in its StarDrop platform

The new Idea Tracker capability further improves the efficiency of drug discovery by supporting project management, idea sharing and molecule design tracking.

BugBiome secures investment for pioneering research in sustainable pest protection

BugBiome raises £310,000 in pre-seed investment from Cambridge Angels and Discovery Park Ventures. Investment enables a £330,000 Engineering Biology Grant from Innovate UK for cutting-edge agri-tech research leveraging the microbiome and engineering biology approaches.

Study reveals POLB 001 could be a $10 billion game changer for cancer patients

Independent Research Confirms >$10bn Market Opportunity for POLB 001 as a Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS). Former Amryt Pharma team's arrival supports increasing focus upon Rare and Orphan Diseases

Demand for Golden Triangle lab space surges with highest annual volume since 2015

Demand for life sciences space in the ‘Golden Triangle’ surged in 2023, with the 925,000 sq ft of space representing the highest annual volume since 2015, according to the latest figures from Cushman & Wakefield.

New £100 million engineering biology fund

Six new Engineering Biology Mission Hubs and 22 Mission Awards, to transform solutions in areas like vaccine development, textile manufacturing and food production; New investments to unlock potential of engineering biology as part of the wider National Engineering Biology Programme

Pioneer Group’s regeneration plans for Cambridge’s Grafton Centre approved

Pioneer Group, a leading developer and operator of life science and high-tech campuses, has secured planning permission from Cambridge City Council, subject to S106, for the redevelopment of the Grafton Centre in the city.

Novel drug and software combo tackles hypertension with personalised treatment

Closed Loop Medicine Ltd., a leading TechBio company developing combination prescription drug plus software therapy products that deliver personalised dose optimisation, today announced the publication of a peer-reviewed study in the Journal of the American Heart Association (JAHA) (1).

 

More within